Completed PHASE2 INTERVENTIONAL NCT00079755

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma

Sponsor: Seagen Inc.

Conditions Anaplastic Large-Cell Lymphoma

Interventions SGN-30 (anti-CD30 mAb)

Updated 7 times since 2017 Last updated: Dec 17, 2014 Started: Feb 29, 2004 Primary completion: Dec 31, 2006 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Anaplastic Large-Cell Lymphoma and is currently completed. Seagen Inc. leads this study, which shows 7 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Seagen Inc.

Data source: Seagen Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Birmingham, United States , Boston, United States , Buffalo, United States , Chicago, United States , Durham, United States , Houston, United States , Los Angeles, United States , Miami, United States , Minneapolis, United States and 7 more locations